NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual M...
NGM Biopharmaceuticals, Inc. (NGM)
Last ngm biopharmaceuticals, inc. earnings: 3/17 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA. Poster Presentation Details: Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalationPresenter: Judy Wang, M.D., Associate Director, Drug Development Unit, Sarah Cannon Research Institute and Florida Cancer SpecialistsAbstract #: CT099Poster Session: First-in-Human Phase I Clinical Trials 1Location: Poster Section 48Date and Time: Monday, April 8th; 1:30 – 5:00 pm PT This p
Show less
Read more
Impact Snapshot
Event Time:
NGM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGM alerts
High impacting NGM Biopharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NGM
News
- NGM Bio Announces Closing of Tender Offer [Yahoo! Finance]Yahoo! Finance
- NGM Bio Announces Closing of Tender OfferGlobeNewswire
- Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law FirmGlobeNewswire
- IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the FirmAccesswire
- INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the FirmAccesswire
NGM
Earnings
- 3/11/24 - Beat
NGM
Sec Filings
- 4/5/24 - Form 25-NSE
- 4/5/24 - Form SC
- 4/5/24 - Form S-8
- NGM's page on the SEC website